Navigation Links
The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
Date:6/6/2008

SAN FRANCISCO, California, June 6 /PRNewswire/ --

- "ADVANCE Results go Beyond Existing Evidence"

New results from the world's largest ever study of diabetes treatments show that intensive blood glucose (sugar) control using modified release gliclazide and other drugs as required, protects patients against serious complications of the disease. In particular, intensive treatment reduces the risk of kidney disease by one-fifth. Presented today at the American Diabetes Association and published in the New England Journal of Medicine, the results of ADVANCE (Action in Diabetes and Vascular Disease) show that this intensive treatment strategy has the potential to benefit millions of diabetic patients worldwide.

Diabetes mellitus is one of the greatest threats to the health of populations worldwide. Globally, there are approximately 250 million people with diabetes and that number is estimated to rise to 380 million in 2025.

Chief investigator of the study, Professor Stephen MacMahon, Principal Director of The George Institute, Australia said "We are facing a global epidemic of diabetes. The ADVANCE results go beyond existing evidence as we have now shown that reducing the haemoglobin A1c level (a marker of blood glucose control) to 6.5% is a safe and effective way to reduce serious complications, particularly the risk of kidney disease, one of the most serious and disabling consequences of diabetes, leading to death in one in five people with diabetes."

"Hypoglycemia (low blood sugar) was uncommon in the ADVANCE study, although as expected it was more frequent among those receiving intensive treatment," pointed out Study Director, Associate Professor Anushka Patel from The George Institute. "These findings reinforce that blood glucose lowering in diabetes is safe and has an important role to play in the prevention of serious complications."

"Moreover, in contrast to the recently halted ACCORD study, there was no evidence w
'/>"/>

SOURCE ADVANCE
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
3. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
4. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
5. Raydiance Collaborates With Rutgers University and Nations Largest Tissue Bank to Develop Innovative Tissue Processing Approaches
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
8. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
9. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... Calif. , July 10, 2014 Integrated ... leader in advanced memory and analog IC solutions, today ... on Thursday, July 24, 2014, at 7:00 a.m. Pacific ... financial results for the fiscal 2014 third quarter ended ... call via telephone, dial 1-888-556-4997 before 6:50 a.m. Pacific ...
(Date:7/10/2014)... Quebec , July 10, 2014  Valeant Pharmaceuticals ... VRX) today announced it has completed the sale to ... and Dysport owned or held by Valeant for $1.4 ... with Nestle S.A, which recently completed its acquisition of ... the divestiture of our products to a company that ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... ActivBiotics, Inc. today,announced the results of its ... rifalazil in the treatment of intermittent claudication,associated ... demonstrated,that treatment for two months with the ... significant improvement in walking distance,claudication onset times, ...
... Scientific Sessions ... 2007 in Orlando, Florida, ... ) today announced the successful completion,of its Phase 2b trial ... vaccine being,developed to treat nicotine addiction and prevent smoking relapse. ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/13/2014)... Nature Genetics identifies a novel genetic and ... esophagitis (EoE), opening up potential new therapeutic strategies ... , EoE is a chronic inflammatory disorder of ... hypersensitivity to certain foods and an over-accumulation in ... (part of the body,s immune system). EoE can ...
(Date:7/13/2014)... North American water storage systems market is estimated to grow ... at a CAGR of 21.0%, from 2013 to 2018. The ... in North America. The U.S. is experiencing high growth on ... and collection, and the increased spending on modernization and upgradation ... rate in Canada, and is rising at a rapid pace ...
(Date:7/13/2014)... July 13, 2014 According to ... and Computing Market by Component (processor, GPU, DSP, ... MDA, Medical), and Geography - Forecast and Analysis ... Mobile Processing & Computing Market is expected to ... CAGR of 20.75% from 2014 to 2020. , ...
(Date:7/13/2014)... Athletes with a certain genetic make-up ... according to research presented today at the American Orthopaedic ... The research marks the first of its kind investigating ... physical events that occur after a head injury. ... in the (GT)n genotype were four times more likely ...
(Date:7/13/2014)... Fadhits.com is popular among worldwide women. Its ... beautiful. Recently, the company has announced its new selection ... more, all these outfits are available at discounted prices ... the supplier is now offering similar discounts for many ... has many other designs for sale, including flower girl ...
Breaking Medicine News(10 mins):Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 2Health News:Study finds cause of mysterious food allergy, suggests new treatment strategy 3Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 2Health News:North American Water Storage Systems Market is Expected to Reach $5,450 million by 2018 - New Report by MicroMarket Monitor 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Heterogeneous Mobile Processing & Computing Market Worth $61.70 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2
... Gardner HealthDay Reporter , TUESDAY, Aug. 31 (HealthDay ... a strong policy statement directed toward pediatricians, parents and the ... are getting about sex from television, the Internet and other ... Media , was published online Aug. 30 and in the ...
... the National Institutes of Health and University of Chicago ... mice reduces the severity of skin and soft-tissue damage ... Staphylococcus aureus infections in the United States. By ... found they could greatly reduce the damaging effects of ...
... lawsuit about gay marriage, the talk at some point turns ... parents? Will their children whether adopted, conceived with the ... relationship adjust, adapt and succeed in a world dominated ... giving them, and come dressed in anecdotes and colored by ...
... (August 31, 2010) A new study ... Massachusetts General Hospital (MGH) suggests that S-Adenosyl Methionine ... effective, relatively well-tolerated, adjunctive treatment for adults with ... their treatment with antidepressant medication. This first-of-its-kind ...
... vaccination of healthcare personnel is a professional and ... regarding vaccination should not be tolerated, according to ... for Healthcare Epidemiology of America (SHEA). The paper, ... Healthcare Epidemiology journal and endorsed by the ...
... OAK BROOK, Ill. A study of triathletes published in ... reveals that the heart adapts to triathlon training by working ... first study using MRI to investigate effects of triathlon training ... associate professor at the University of Erlangen-Nuremberg in Erlangen, Germany. ...
Cached Medicine News:Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 2Health News:U.S. Pediatricians Decry Media's Portrayal of Sex 3Health News:Treatment for S. aureus skin infection works in mouse model 2Health News:Treatment for S. aureus skin infection works in mouse model 3Health News:Children raised by gay couples show good progress through school 2Health News:Children raised by gay couples show good progress through school 3Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 2Health News:Study findings show value of dietary supplement SAMe in treatment of adults with major depressive disorders 3Health News:Nation's leading ID experts call for mandatory flu vaccine for all health-care personnel 2Health News:Combining resistance and endurance training best for heart health 2
Calcitonin EIA Bone and Mineral Metabolism 021-SDX017...
... an enzyme immunoassay (EIA) kit for the ... the subclass of Anti-Neutrophil Cytoplasmic Antibodies (ANCA) ... an aid in the diagnosis of crescentic ... with vasculitic disorders and glomerulonephritis (GN). They ...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-96 Proteinase...
Anti-PR3 EIA Auto-Immune Markers 013-PR3-48 Proteinase...
Medicine Products: